<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905578</url>
  </required_header>
  <id_info>
    <org_study_id>201801759</org_study_id>
    <secondary_id>3P30CA086862</secondary_id>
    <secondary_id>5U01CA140206</secondary_id>
    <nct_id>NCT02905578</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)</brief_title>
  <official_title>A Phase II Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer (PACMAN 2.1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph J. Cullen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGuff Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for
      metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized
      between a control group (standard treatment) and an intervention group (pharmacologic
      ascorbate in addition to the standard treatment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the standard treatments for metastatic pancreatic adenocarcinoma is nab-paclitaxel
      with gemcitabine. This standard therapy administers chemotherapy once per week for three
      weeks; patients then get a 'rest week' to complete the cycle (1 cycle = 4 weeks).

      This study adds 75 grams of ascorbate (vitamin C, sometimes called pharamcological ascorbate
      because the dose is so high) to standard therapy. The ascorbate is administered intravenously
      - through a vein in the arm.

      Participants in the control group will:

        -  receive gemcitabine and nab-paclitaxel chemotherapy, which is standard for their cancer.

        -  undergo imaging which is standard for their cancer and therapy. This can include CT
           scans, PET scans, and X-rays

      Participants in the intervention group will:

        -  receive 75 grams of ascorbate 3 times per calendar week for each week of the
           chemotherapy cycle.

        -  undergo imaging which is standard for their cancer and therapy. This can include CT
           scans, PET scans, and X-rays

        -  provide blood samples to determine the biological effects, if any, the ascorbate has on
           the body during therapy.

      This active therapy portion lasts until the disease progresses and a new treatment needs to
      be adopted - this can be months to years. If disease progresses, participants go back to
      standard follow-up for their caner and the new/additional therapy their doctors prescribe.

      However, it is very important we remain in contact with participants; they will have
      life-long follow-up for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 2 months for up to 20 years post-treatment</time_frame>
    <description>Time, measured in months, from the start of chemotherapy (C1D1) to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>Every 2 months for up to 10 years</time_frame>
    <description>Determine the objective response rate of the disease, assessed every 2 months using CT or MRI, and evaluated/defined using the RECIST criteria (v1.1). Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Every 2 months for up to 10 years</time_frame>
    <description>Time, measured in days, it takes disease to progress, where disease progression is defined by the RECIST criteria (v1.1). Timeframe is from radiation day 1 to date of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event frequency and categorization</measure>
    <time_frame>Monthly through 30 days after end of treatment.</time_frame>
    <description>Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (CTCAE v4). Assessments will be monthly through 30 days past the end of therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Cancer of Pancreas</condition>
  <condition>Cancer of the Pancreas</condition>
  <condition>Neoplasms, Pancreatic</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreas Neoplasms</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ascorbate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is 4 calendar weeks
Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each cycle is 4 calendar weeks
Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate
given for 3 weeks out of the 4 week cycle
standard dose reductions are used
up to 2 cycles are administered before standard of care CT scan
decision to continue therapy is based disease response to therapy as measured from the CT scan
treatment continues until disease progression is identified</description>
    <arm_group_label>Ascorbate group</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Gemcitabine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate
given for 3 weeks out of the 4 week cycle
standard dose reductions are used
up to 2 cycles are administered before standard of care CT scan
decision to continue therapy is based disease response to therapy as measured from the CT scan
treatment continues until disease progression is identified</description>
    <arm_group_label>Ascorbate group</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacological ascorbate</intervention_name>
    <description>Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine
given 3 times weekly
given for 4 weeks out of the 4 week cycle
no dose reductions are used
up to 2 cycles are administered before standard of care CT scan
decision to continue therapy is based disease response to therapy as measured from the CT scan
treatment continues until disease progression is identified</description>
    <arm_group_label>Ascorbate group</arm_group_label>
    <other_name>Ascorbate</other_name>
    <other_name>Vitamin C</other_name>
    <other_name>Ascorbic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis (cell samples, biopsy, brushing, surgical sample) of
             adenocarcinoma of the pancreas. Cancer from the Ampullae of Vater is also eligible.
             The tissue sample can be from a metastatic location, like a lymph node.

          -  Metastatic or node positive disease

          -  One cancer site, that did not receive radiation therapy, that is at least 1 cm in size
             when looking at it by CT scan (CAT scan)

          -  Recommended to receive gemcitabine and nab-paclitaxel

          -  Failed initial therapy or be ineligible for definitive curative therapy (e.g.,
             surgical excision, radiation therapy)

          -  A platelet count of at least 100,000 cells per mL

          -  A creatinine level of less than 1 1/2 times the upper limit of normal for the local
             lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)

          -  Not pregnant

          -  Commit to using birth control during the study (all participants)

        Exclusion Criteria:

          -  Prior chemotherapy to treat the metastatic disease

          -  Other therapy (including radiation) within the past 4 weeks

          -  Side effects from prior therapies that are still deemed moderate to severe by a
             physician

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Patients actively receiving insulin or who are currently recommended to receive
             insulin by a doctor

          -  Patients requiring daily finger-stick blood glucose measurements

          -  Patients who are on the following drugs and cannot have a substitution (or who decline
             the substitution):

               -  warfarin

               -  flecainide

               -  methadone

               -  amphetamines

               -  quinidine

               -  chlorpropamide

          -  An active cancer, other than the pancreatic cancer, that requires treatment.

          -  Enrolled in another therapeutic clinical trial

          -  Uncontrolled, intercurrent illness

          -  HIV positive individuals undergoing therapy due to known drug:drug interaction between
             antiretroviral drugs and high-dose ascorbate therapy

          -  Women who are nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J. Cullen, MD, FACS</last_name>
    <role>Study Director</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph J. Cullen, MD, FACS</last_name>
    <phone>319-353-8297</phone>
    <email>joseph-cullen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel J. Berg, MD</last_name>
    <phone>319-353-7800</phone>
    <email>daniel-j-berg@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt, RN, BSN, OCN</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown, RN, BAN, OCN</last_name>
      <phone>(319) 384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Berg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Cullen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Doskey CM, Buranasudja V, Wagner BA, Wilkes JG, Du J, Cullen JJ, Buettner GR. Tumor cells have decreased ability to metabolize H(2)O(2): Implications for pharmacological ascorbate in cancer therapy. Redox Biol. 2016 Dec;10:274-284. doi: 10.1016/j.redox.2016.10.010. Epub 2016 Oct 28.</citation>
    <PMID>27833040</PMID>
  </reference>
  <reference>
    <citation>Du J, Cieslak JA 3rd, Welsh JL, Sibenaller ZA, Allen BG, Wagner BA, Kalen AL, Doskey CM, Strother RK, Button AM, Mott SL, Smith B, Tsai S, Mezhir J, Goswami PC, Spitz DR, Buettner GR, Cullen JJ. Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Cancer Res. 2015 Aug 15;75(16):3314-26. doi: 10.1158/0008-5472.CAN-14-1707. Epub 2015 Jun 16.</citation>
    <PMID>26081808</PMID>
  </reference>
  <reference>
    <citation>Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(â‹…-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.</citation>
    <PMID>28366679</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Joseph J. Cullen</investigator_full_name>
    <investigator_title>Professor, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>Ascorbate</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Pharmacological ascorbate</keyword>
  <keyword>Pharmacologic ascorbate</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Abraxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared per consent document, governing Federal regulations and institutional policies, and only after a signed sharing agreement between the sponsor and the requesting investigator.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Initial requests can be submitted to the sponsor Joseph Cullen, MD, FACS at any time with a description as to the information needed.</ipd_time_frame>
    <ipd_access_criteria>A signed usage and confidentiality agreement must be executed prior to data sharing.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

